These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8385015)

  • 1. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.
    Micozzi A; Nucci M; Venditti M; Gentile G; Girmenia C; Meloni G; Martino P
    Eur J Clin Microbiol Infect Dis; 1993 Jan; 12(1):1-8. PubMed ID: 8385015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis.
    Martino P; Micozzi A; Gentile G; Raccah R; Girmenia C; Mandelli F
    Clin Infect Dis; 1992 Aug; 15(2):290-4. PubMed ID: 1387806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
    Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
    J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Rizal AM; Nordiah AJ; Jamal R
    Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
    Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients.
    Fleischhack G; Schmidt-Niemann M; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    Support Care Cancer; 2001 Jul; 9(5):372-9. PubMed ID: 11497392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'étude des Aplasies Fébriles].
    Marie JP; Vekhoff A; Cony-Makhoul P; Fière D; Guy H; Herbrecht R; Milpied N; Pico JL; Plantier I
    Presse Med; 1995 Feb; 24(8):397-401. PubMed ID: 7899419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
    Zengin E; Sarper N; Kılıç SC
    Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
    Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
    Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients.
    Micozzi A; Venditti M; Amadori S; Pulsoni A; Tirindelli C; Martino P
    Br J Haematol; 1990 Dec; 76 Suppl 2():19-23. PubMed ID: 2149046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
    Rossini F; Terruzzi E; Verga L; Larocca A; Marinoni S; Miccolis I; Giltri G; Isella M; Parma M; Pogliani EM
    Support Care Cancer; 2005 Jun; 13(6):387-92. PubMed ID: 15599778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
    Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
    Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies.
    Hazel DL; Graham J; Dickinson JP; Newland AC; Kelsey SM
    J Chemother; 1997 Aug; 9(4):267-72. PubMed ID: 9269607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.
    Del Favero A; Menichetti F; Martino P; Bucaneve G; Micozzi A; Gentile G; Furno P; Russo D; D'Antonio D; Ricci P; Martino B; Mandelli F;
    Clin Infect Dis; 2001 Oct; 33(8):1295-301. PubMed ID: 11565068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.